These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 32208486)

  • 21. Finding Effective Treatments for COVID-19: Scientific Integrity and Public Confidence in a Time of Crisis.
    Goodman JL; Borio L
    JAMA; 2020 May; 323(19):1899-1900. PubMed ID: 32297900
    [No Abstract]   [Full Text] [Related]  

  • 22. Favipiravir, an antiviral for COVID-19?
    Coomes EA; Haghbayan H
    J Antimicrob Chemother; 2020 Jul; 75(7):2013-2014. PubMed ID: 32417899
    [No Abstract]   [Full Text] [Related]  

  • 23. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology.
    Dal Moro F; Livi U
    Clin Immunol; 2020 May; 214():108414. PubMed ID: 32272196
    [No Abstract]   [Full Text] [Related]  

  • 24. ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic.
    Stolbach AI; Mazer-Amirshahi M; Marino R; Nelson LS; Sugarman J
    J Med Toxicol; 2020 Jul; 16(3):342-345. PubMed ID: 32500283
    [No Abstract]   [Full Text] [Related]  

  • 25. COVID-19 therapeutic options for patients with kidney disease.
    Izzedine H; Jhaveri KD; Perazella MA
    Kidney Int; 2020 Jun; 97(6):1297-1298. PubMed ID: 32317113
    [No Abstract]   [Full Text] [Related]  

  • 26. Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19.
    Monte Serrano J; Cruañes Monferrer J; García-García M; García-Gil MF
    Med Clin (Barc); 2020 Sep; 155(5):231. PubMed ID: 32522372
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pharmacological options in treating SASR-CoV-2 infection/COVID-19].
    Fábián Á; László I; Juhász M; Berhés M; Végh T; Koszta G; Molnár C; Fülesdi B
    Orv Hetil; 2020 Apr; 161(17):685-688. PubMed ID: 32324361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. May drug-related cardiovascular toxicities persist after hospital discharge in COVID-19 patients?
    Kara E; Inkaya AC; Demirkan K
    Int J Antimicrob Agents; 2020 Jun; 55(6):106003. PubMed ID: 32360773
    [No Abstract]   [Full Text] [Related]  

  • 29. Prescribing COVID-19 treatments: what we should never forget.
    Tunesi S; Bourgarit A
    J Infect; 2020 Aug; 81(2):e85. PubMed ID: 32405110
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug Evaluation during the Covid-19 Pandemic.
    Rome BN; Avorn J
    N Engl J Med; 2020 Jun; 382(24):2282-2284. PubMed ID: 32289216
    [No Abstract]   [Full Text] [Related]  

  • 31. Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval.
    Thomson K; Nachlis H
    JAMA; 2020 Oct; 324(13):1282-1283. PubMed ID: 32870235
    [No Abstract]   [Full Text] [Related]  

  • 32. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?
    Alany RG
    Pharm Dev Technol; 2020 Jul; 25(6):649. PubMed ID: 32423342
    [No Abstract]   [Full Text] [Related]  

  • 33. [Chloroquine as a possible treatment for COVID-19].
    Coumou J; de Vries PJ
    Ned Tijdschr Geneeskd; 2020 Mar; 164():. PubMed ID: 32391999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thalidomide Should Be Tested as a Therapeutic Option in COVID-19 Pneumonia.
    Tiscornia JE; Poggio TV; Feinsilber DG; Coleman AE
    Skinmed; 2020; 18(4):254-255. PubMed ID: 33050993
    [No Abstract]   [Full Text] [Related]  

  • 35. Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19.
    Rubin R
    JAMA; 2020 Jun; 323(21):2114-2117. PubMed ID: 32352484
    [No Abstract]   [Full Text] [Related]  

  • 36. Discovering small-molecule therapeutics against SARS-CoV-2.
    Tiwari V; Beer JC; Sankaranarayanan NV; Swanson-Mungerson M; Desai UR
    Drug Discov Today; 2020 Aug; 25(8):1535-1544. PubMed ID: 32574699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions.
    Magaret AS; Jacob ST; Halloran ME; Guthrie KA; Magaret CA; Johnston C; Simon NR; Wald A
    Ann Intern Med; 2020 Oct; 173(7):576-577. PubMed ID: 32525715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
    Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
    Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. World War against COVID-19: How strong is our armamentarium?
    Ramachandran V; Marimuthu RR; Chinnambedu RS
    Med J Malaysia; 2020 May; 75(3):314-315. PubMed ID: 32467555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.